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ABSTRACT 
 
Thirty-six years after the first identification of AIDS, the spread of its aetiological agents continues 
unabated, human immunodeficiency virus 1 (HIV-1) in particular. About 40% of HIV-1 infections have 
been reported to initiate in the female reproductive tract (FRT). However, the biological mechanisms 
through which these infections are spread are poorly understood hence there is now a major concern in 
women who use injectable hormonal contraceptives, particularly medroxyprogesterone acetate (MPA) 
administered as depot medroxyprogesterone acetate (DMPA) or Depo-Provera and an increase of HIV-
1 risk acquisition.  
 
As per literature, the glucocorticoid receptor (GR) and progesterone receptor (PR) are the main targets 
for Depo-Provera in the FRT. Therefore, in this study we performed molecular dynamic (MD) 
simulation on both the GR and the PR systems in relation to DMPA as a way of validating their docking 
poses and binding energy trends. We also investigated the nature of their overall interaction themes 
using post-dynamic analysis and most importantly, we postulated possible biological mechanisms in 
which DMPA may act via the GR and the PR in association with increased risk of HIV-1 infection in 
women. 
 
Our findings revealed that, the effect of DMPA binding to both the GR and the PR could have a great 
impact on increased risk of HIV-1 infection in women. The reason being that when these receptors are 
activated by an agonist DMPA, they interact with a few residues in the ligand binding domain (LBD) 
which could affect the stability state of these receptors. They also interact with NFϰB transcription 
factor as well as the p300 coactivator in the nucleus to cause transactivation in the ectocervical 
(Ect1/E6E7) epithelial cell line of the FRT, in turn, increasing mRNA and protein secretion levels of 
proinflammatory cytokines.   
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CHAPTER 1 
1. Introduction 
 
1.1 Background & Rational 
 
Acquired immune deficiency syndrome (AIDS) was first recognised as a new disease in 1981, but it 
became a more serious condition over the past years as its global statistics was revealed to increase 
every year (Sharp and Hahn,2011). The causative agent for this disease is Human Immunodeficiency 
Virus (HIV) which can further be classified into HIV-1 and HIV-2, with HIV-1 reported to be the major 
source of the AIDS pandemic (Dey et al., 2014; Plantier et al., 2009). Both HIV-1 and HIV-2 belong to 
the genus Lentivirus family of Retroviridae (Sharp and Hahn, 2010; Wain et al., 2007). Globally, 
HIV/AIDS is widely spread in sub-Saharan Africa (SSA) and Asia with the morbidity & mortality rate 
highest in young adults, women revealed to be the most vulnerable (Dey et al., 2014; Gouws et al., 
2008; Sharp and Hahn, 2011). The method through which humans acquired ape precursors of HIV is 
poorly understood. However, it is believed that they could have come into contact with infected blood 
or other body fluid of these apes perhaps during hunting (Sharp and Hahn,2011). 
 
An estimation of over 50 million women worldwide use Depo-Provera as a way of preventing 
pregnancy hence this has become one of the major reasons associated with their susceptibility to HIV 
infection (Hel et al., 2010; Morrison et al., 2012). Depo-Provera acts by binding to and regulating the 
activity of steroid receptors. Herein, we focussed our attention on the Glucocorticoid receptor (GR) and 
the Progesterone receptor (PR) as they are the main targets for Depo-Provera in the FRT (Schindler et 
al., 2003; Tomasicchio et al., 2013). Both GR and PR consist of various conserved domains at the centre 
but in this study, the ligand binding domain (LBD) was of great interest. Therefore, we performed 
molecular docking and molecular dynamic (MD) simulations on both the GR and PR protein systems 
in relation to Depo-Provera. 
 
We also investigated their overall interaction themes using post dynamic analysis whereby 50 ns 
multiple MD simulations were employed to gain insight into the effect of Depo-Provera on the GR and 
PR. This was followed by binding free energy calculations, root mean square deviation (RMSD), root 
mean square fluctuation (RMSF) and radius of gyration (Rg) analyses. 
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1.2 Aim & objectives 
 
The major aim of this work was to investigate possible biological mechanisms in which Depo-Provera 
may act via the GR & the PR signalling pathways in association with increased risk of HIV-1 infection 
in women. To accomplish this, the following objectives were outlined:  
 
1. To estimate different binding affinities and orientations using molecular docking for Depo-Provera  
bound to the GR and the PR, respectively. 
 
2. To validate docking poses and binding energy trends for Depo-Provera bound to the GR and the PR  
systems using half maximal effective concentration (EC50) values and docking scores of the 
related approved drugs. 
 
3. To perform 50ns multiple MD simulations for further verification on the resulted-docked systems. 
 
4. To quantify individual amino acid interactions towards the total binding free energy and interaction  
forces (i.e. intramolecular and intermolecular forces computed per-residue interactions using 
MM/PBSA approach). 
 
5. To investigate the nature of the overall interaction themes between Depo-Provera bound to the GR  
& PR target proteins and specific amino acids involved in ligand binding using post-dynamic 
analyses.         
 
1.3 Novelty and significance of study 
 
Antiretroviral therapy (ART) controls viral replication, restores the immune function and reduces viral 
load in HIV infected individuals (Katlama et al., 2013; UNAIDS, 2013). This treatment has been the 
medical solution against HIV/AIDS and it has been effective in reducing the number of death rates 
caused by the disease (Katlama et al., 2013; Sharp and Hahn,2011). However, it is incapable of 
destroying the virus completely and reliability on it for future curative abilities is uncertain (Sharp and 
Hahn,2011). Depo-Provera on the other hand, has been identified as one of the major risk factors 
associated with increased risk of HIV-1 in women (Ralph et al., 2015; Tomasicchio et al., 2013). 
However, the mechanisms through which it places women at risk are poorly understood. Likely, 
Schindler et al (2003) reported both the GR and PR as the main targets for Depo-Provera in the FRT 
since their biological activities are essential (Schindler et al., 2003).  
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This information is worth noting as it could mean that the GR and PR have effects on HIV-1 
pathogenesis upon binding of Depo-Provera, particularly in the immune function. Therefore, we found 
it necessary to investigate HIV-1 pathogenesis in the FRT via the GR and PR signalling pathways in 
response to the effect of Depo-Provera. By conducting this research, we aim to provide new insights 
that will be useful in the development of new drugs against HIV/AIDS. A minimum of two articles will 
be published from this work and a thesis for an MSc in Medical Science degree will be submitted to the 
University of KwaZulu-Natal. 
                                                                                                                                                                                                                                                                                                                                    
1.4 Overview of thesis 
 
This thesis is divided into six chapters, chapter 1 included. Brief explanation of chapter 2, 3, 4, 5 & 6 
is explained below: 
 
Chapter 2 
Explains the spread of HIV/AIDS across different countries. 
 
Chapter 3 
Discusses the background information of Molecular Modelling and provides brief explanation of the 
computational techniques performed in this study. 
 
Chapter 4 (Accepted manuscript- this chapter is presented in the required format of the journal 
and is the final accepted version) 
This is a review paper from the study titled “Review on the biological mechanisms associated with 
Depo-Provera and HIV-1 risk acquisition in women”. It provides relevant literature that could be 
linked with the relationship between Depo-Provera and increased risk of HIV-1 acquisition in women. 
 
Chapter 5 (Submitted manuscript- this chapter is presented in the required format of the journal 
and is the final submitted version) 
This is a research article from the study titled “Computational modelling of DMPA interactions with 
GR and PR in association with increased risk of HIV-1 infection in women”. It addresses objectives 1-
5 as explained above. 
 
Chapter 6 
This chapter provides general conclusion of the overall thesis and future recommendations for future 
studies.  
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CHAPTER 2 
 
2. Introduction 
 
This chapter explains the spread of HIV/AIDS across different countries. A detailed literature of this 
study is explained in chapter 4 (Review Paper). 
 
2.1 The spread of HIV/AIDS 
 
HIV/AIDS was first reported in the United States of America (USA) where it infected about 75 million 
individuals (Faria et al., 2014). It then spread to other countries such as South Africa (SA) where it 
infected approximately 6 million individuals (Kleinschmidt et al., 2007). In 1991, the AIDS global 
programme at World Health Organisation (WHO) predicted that by 2000 the cumulative global total of 
HIV infections in men, women and children would be 40 million. However, the cumulative global total 
of HIV infections appeared to be 56 million, proving a serious underestimate in the prediction (Piot et 
al., 2001).  At the end of 2000, the region reported to have the worst epidemic was SSA with an 
estimation of 25.3 million people living with HIV (Piot et al., 2001).  
 
In 2002, WHO reported 42 million people worldwide infected with HIV/AIDS while on the other hand, 
Simon et al (2006) reported about 46 million individuals worldwide infected with HIV-1 and 
approximately 25 million individuals already dead (Alimonti et al., 2003; Simon et al., 2006). Recent 
update (2016) provided by the TenoRes study group revealed more than 35 million people worldwide 
living with HIV-1 (Gregson et al., 2016). Up to date, the spread of HIV/AIDS is still estimated to 
increase across different countries yet the cure for this disease remains an ongoing challenge (Piot et 
al., 2001). The high vulnerability of women to HIV infection consequently places them at risk of 
transmitting the virus which in most cases can either be through direct transmission (mother to child) 
or horizontal transmission (heterosexual contact) (Anderson et al., 1991; Morison et al., 2001). 
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CHAPTER 3 
3. Methods 
 
This chapter introduces the concept of Molecular Modelling and provides brief explanation of some 
computational techniques performed in this study such as molecular docking, molecular dynamic 
simulation and thermodynamic calculations. Further explanation of these techniques continues in 
chapter 5 (Research Article Paper). 
 
3.1 Introduction to Molecular Modelling 
 
Molecular modelling, term used synonymously with computational chemistry, provides tools for doing 
and teaching chemistry better, allowing scientists to investigate, interpret, explain and discover new 
phenomena (Nadendla, 2004). It uses computers to construct molecules and predict their chemical 
characteristics and behaviour by performing variety of calculations (Mukesh and Rakesh, 2011). 
Molecular modelling mimics the behaviour of molecules using computational techniques, data from 
experiments and all theoretical chemistry methods to predict molecular and biological properties 
(Nadendla, 2004). The level of description of atoms in molecular systems is a common feature of the 
molecular modelling technique (Rodrigues et al., 2008). Thus, molecular modelling technique allows 
consideration of atoms during simulation by reducing the system’s complexity (Mukesh and Rakesh, 
2011). 
 
3.2 Molecular docking  
 
Molecular docking is a computer based approach used to discover new compounds of therapeutically 
relevance using known target protein structures (Mukesh and Rakesh, 2011). The interest of molecular 
docking is to reproduce chemical potentials to estimate the binding affinity of a ligand within the 
receptor binding site and to predict bound conformations (Guedes et al., 2014; Trott and Olson, 2010). 
During the process of molecular docking, there are some conformational adjustments (referred to as 
“induced fit”) that occur between the ligand and the protein to achieve what is referred to as the overall 
“best fit” (Mukesh and Rakesh, 2011).  
 
These adjustments include optimal conformation of the ligand and the protein as well as their relative 
orientation (Figure 3.1) (Mukesh and Rakesh, 2011).  Docking methodologies are useful in planning 
and designing of new drugs in addition to predicting the strength and type of signal produced (Guedes 
et al., 2014; Mukesh and Rakesh, 2011). Docking may also be applied to bioremediation, hit 
identification and lead optimization (Mukesh and Rakesh, 2011). 
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Figure 3.1 Optimized conformation of the ligand & the protein receptor. Figure adapted from Mukesh 
et al 2011 (Mukesh and Rakesh, 2011). 
 
Whether the docked conformation is good or bad can be determined based on Dock score, scoring 
functions or sum of steric and electrostatic Merc Molecular Force Fields (MMFF) (Mukesh and Rakesh, 
2011).  For a docking programme to be successful, two main components should be considered: (i) the 
search algorithm and (ii) the scoring function (Mukesh and Rakesh, 2011). These are the basic tools 
used to generate and evaluate ligand conformation (Guedes et al., 2014). Docking softwares include 
Auto Dock, Dock, Gold, V Life MDS, CDOCKER and Flex X (Erickson et al., 2004; Mukesh and 
Rakesh, 2011; Wandzik, 2006).  
 
In this study, we used Auto Dock Vina which is an improved version of Auto Dock. This software uses 
a method known as sophisticated gradient optimization which allows better accuracy to predict the 
binding mode and has been shown to improve the speed by approximately two orders of magnitude 
compared to Auto Dock (Trott and Olson, 2010).  
 
3.3 Molecular Dynamic (MD) simulations 
 
Molecular dynamics is one of the major computational methods used to calculate properties of 
molecules (Nadendla, 2004). The aim of MD simulation is to understand properties of a group of 
molecules by looking at their structures and the microscopic interaction between them (Allen, 2004). 
These interactions comprise non-bonded interactions, bonding potentials and force calculations (Allen, 
2004). Simulation softwares are designed in packages such as AMBER, OPLS, CHARMM and many 
others (Crowley et al., 2009; Van Gunsteren and Mark, 1998). In this study, we used AMBER software 
to carry out MD simulations. More than 40 scientific researchers have collaborated to get AMBER 
software running to solve biochemistry problems. To date, it is installed in more than 1000 sites 
worldwide (Salomon-Ferrer et al., 2012). This is a software which refers to simulation of biomolecules 
by a series of classical molecular mechanic’s force fields (Salomon-Ferrer et al., 2012). 
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It includes general organic molecules (GAFF), amino acid and nucleic acid parameter sets (ff94, ff99SB 
& ff12SB), carbohydrates (Glycam) and phospholipids (Lipid11) (Salomon-Ferrer et al., 2012). The 
AMBER package also contains three main MD engines which are sander, pmend and pmend.cuda 
(Crowley et al., 2009; Salomon-Ferrer et al., 2012). Herein, the pmend.cuda engine which is a graphics 
processing unit (GPU)-accelerated version of pmend was utilised (Case et al., 2015; Salomon-Ferrer et 
al., 2012). In addition to this, AmberTools including LEaP, Antechamber, chamber, paramfit and Metal 
Center Parameter Builder (MCPB) were used to prepare for simulation while on the other hand, ptraj, 
cpptraj, pbsa and Mmpbsa tools were used to analyse MD simulations (Salomon-Ferrer et al., 2012).  
 
3.4 Thermodynamic calculations 
 
Two approaches are widely used to calculate binding free energies of ligands to proteins or proteins to 
proteins complexes: (i) Molecular Mechanics General Born-Surface Area (MM/GBSA) and (ii) 
Molecular Mechanics Poisson Boltzman Surface Area (MM/PBSA) (Fu et al., 2013; Sun et al., 2014). 
Both MM/PBSA and MM/GBSA are classified under free energy end-point methods and are 
implemented in software programmes such as Delphi, Schrödinger and Amber (Gilson and Zhou, 2007; 
Hayes and Archontis, 2012). Therefore, to carry out energy calculations, these approaches use MD 
simulations of a free ligand, free protein as well as their complex (Gilson and Zhou, 2007).  
 
When calculating absolute binding free energies based on MD simulations, the MM/PBSA approach 
has been proven to give better results as compared to the MM/GBSA approach. However, this is not 
necessarily the case when calculating relative binding free energies (Hayes and Archontis, 2012). 
Several factors including charge models, force fields and selection of atomic radius parameters may 
affect the ability of accurate binding free energy estimates (Fu et al., 2013). Nevertheless, we employed 
the MM/PBSA approach implemented in AMBER 14 to evaluate binding free energies of DMPA in 
association with the GR & the PR. Equations to calculate such binding free energies are discussed in 
chapter 5. 
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Abstract 
 
Women constitute more than 50% out of millions of individuals infected with HIV-1, the major 
causative agent of AIDS. About 40% of HIV-1 infections have been reported to initiate in the female 
reproductive tract (FRT). However, the mechanisms through which these infections are spread are 
poorly understood hence there is now a major concern in women who use long acting injectable 
hormonal contraceptives, particularly Depo-Provera and an increase of HIV-1 risk acquisition. Based 
on literature, Depo-Provera has an affinity for both the glucocorticoid receptor (GR) and the 
progesterone receptor (PR) in the FRT. Therefore, investigating HIV-1 pathogenesis in the FRT via the 
GR and the PR mechanisms in response to the effect of Depo-Provera is of great importance.  
 
Key words: HIV-1, Depo-Provera, Glucocorticoid receptor, Progesterone receptor, Female 
reproductive tract. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
14 
 
4.1 Introduction 
 
Human Immunodeficiency Virus (HIV) is the causative agent for the disease that has been recognised 
as a “global killer” since 1980s, the acquired immune deficiency syndrome (AIDS) (Moonsamy et al., 
2014; Sharp and Hahn, 2011). Concerning its subdivisions (HIV-1 and HIV-2), HIV-1 has been 
reported to be the most studied as well as the most widespread. Moreover, this type of virus is divided 
into various groups which are M, N, O & P. Amongst these four groups, M has been revealed to be the 
most pandemic (Sharp and Hahn, 2011). All HIV-1 groups can lead to the depletion of CD4+ T-cells in 
humans which in turn causes AIDS but the difference is how they are distributed within the population 
(Sharp and Hahn, 2011).  
 
Statistics revealed that more than 20 million people have died of HIV infection while about 35 million 
people are infected (Herrera-Carrillo and Berkhout, 2015). It also showed that, women are more 
vulnerable to HIV-1 infections than men accounting for about 59% in sub-Saharan Africa (SSA) 
(Tomasicchio et al., 2013). Three major ways in which HIV-1 can be transmitted is through sexual 
intercourse, percutaneous and perinatal routes (Palmisano and Vella, 2011; Sharp and Hahn, 2011). The 
pathogenicity of HIV-1 is unique hence the mechanisms through which it places women at risk are 
poorly understood.  
 
Previous studies suggested that one of the major risk factors could be that women use long acting 
injectable hormonal contraceptives as a way of preventing pregnancy, particularly 
medroxyprogesterone acetate (MPA) administered as depot medroxyprogesterone acetate (DMPA) or 
Depo-Provera (Polis et al., 2014; Ralph et al., 2015; Tomasicchio et al., 2013). Interestingly, Schindler 
et al (2003) reported that the biological activities of both the glucocorticoid receptor (GR) and the 
progesterone receptor (PR) are essential hence, they are the main targets for Depo-Provera in the FRT 
(Schindler et al., 2003).  
 
From this information, it can be deduced that the GR and the PR could have effects on HIV-1 
pathogenesis upon binding of DMPA, particularly in the immune function. However, further 
investigations regarding how much DMPA dose is responsible for causing an increase of HIV-1 
infection in women still needs to be conducted. Herein, we review possible biological mechanisms 
occurring in the FRT via the GR and the PR in the presence of DMPA which could lead to an increase 
of HIV-1 infection in women. 
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4.2 HIV-1 viral life cycle 
 
The life cycle of HIV is divided into various stages as is explained below and presented in Figure 4.1. 
(1) Binding: This is also known as an attachment stage because the infectious HIV uses its glycoproteins 
to attach itself to the CD4 receptors located on the surface of the cell membrane (NIAID, 2005; 
Palmisano and Vella, 2011). It does so in conjunction with chemokine co-receptors located at the CD4 
T lymphocyte surface such as CCR5 or CXCR4 to make the process of invading the cell easier 
(Engelman and Cherepanov, 2013; NIAID, 2005). (2) Fusion/entry: The HIV envelope fuses with the 
CD4 cell membrane to continue the process of invading the cell (Berger et al., 2007).  
 
(3) Reverse transcription & (4) Nuclear import: HIV uses one of its enzymes known as reverse 
transcriptase to convert its single stranded HIV-RNA to double stranded HIV-DNA in the cytoplasm of 
a CD4 cell to penetrate the nucleus (Berger et al., 2007; NIAID, 2005). (5) Integration: Located in the 
nucleus is the CD4 cell DNA (human DNA). Here, the HIV enzyme integrase is released to allow HIV-
DNA (also referred to as the provirus) to insert itself or form part of the human DNA (Engelman and 
Cherepanov, 2013). (6) Transcription: Upon activation of the host cell by a signal in response to the 
presence of a provirus in the human DNA, small chains of virus proteins are formed during cell division 
(Herrera-Carrillo and Berkhout, 2015; NIAID, 2005). 
 
 This involves strands of HIV genomic material created by the provirus using a host enzyme called 
RNA polymerase and shorter RNA strands known as messenger RNA (mRNA). (7) Translation: Shorter 
mRNA strands give rise to long chains of HIV proteins which are chopped down into smaller proteins 
by HIV protease (NIAID, 2005). (8) Assembly: These smaller HIV proteins migrate to the surface of 
the CD4 cell and together with the newly formed HIV-RNA assemble into harmless immature HIV 
(Herrera-Carrillo and Berkhout, 2015; NIAID, 2005). (9) Maturation: the immature HIV finds its way 
outside the host cell but since it is an enveloped RNA virus, it steals part of host cell’s envelope to cover 
itself (Berger et al., 2007). 
 
 In this way, the immature HIV becomes harmful because the host cell’s envelope contains HIV 
glycoproteins which make it possible for the virus to attach itself again to the CD4 receptors and co-
receptors, producing more new copies of HIV and spreading the infection to other cells (Berger et al., 
2007). 
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Figure 4.1. Steps of the HIV-1 viral life cycle. (1) infectious HIV binds to the surface of the cell, (2) 
infectious HIV enters the cell membrane, (3) & (4) single stranded HIV-RNA is converted to double 
stranded HIV-DNA which enters the nucleus, (5) HIV-DNA forms part of human DNA, (6) small chains 
of virus proteins are formed during cell division including mRNA strands, (7) mRNA strands give rise 
to HIV proteins, (8) HIV proteins migrate to the surface of the cell where it forms harmless immature 
HIV, (9) immature HIV comes into contact with the host’s cell envelope which contains glycoproteins 
and becomes mature harmful HIV. Figure adapted from Herrera-Carrillo and Berkhout (2015). 
 
4.3 Risk factors of HIV-1 
 
The most common mode of infection in adults is through heterosexual transmission whereas in children 
is through mother-to-child transmission which occurs especially during the process of giving birth 
(Mostad et al., 1997). It has been reported that uncircumcised men have an increased risk of HIV 
infection of about 60% (Mmbaga, 2013). However, the joint United Nations programme on HIV/AIDS 
(UNAIDS) revealed that 52% of infected adults are women (Mmbaga, 2013). The cervix and vagina 
could be significant determinants of transmitting the virus sexually and vertically since 51% of HIV-1 
infected cells are detected in the endocervix and 14% are detected in the vagina (Mostad et al., 1997). 
In addition to this, deficiency of vitamin A has been shown to result in shedding of HIV-1 infected cells 
in the vagina. When DMPA is administered, CD4 count is lowered and thickening of the cervical mucus 
in the genital tract is also affected resulting in an increase of the spread of HIV-1 infected cells.  
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Therefore, replication of the virus may either affect immune modulation or physiology of the local 
genital tract due to effects of hormonal contraceptives or vitamin A deficiency (Mostad et al., 1997). 
Every year in SSA, reproductive tract infections (RTIs) are estimated to give rise to new infections such 
as vaginitis, gonorrhoea and chlamydia because of lack of diagnostic services and poor health-seeking 
behaviours (Mmbaga, 2013).  
 
4.4 Components of the immune system in the female reproductive tract (FRT) associated with HIV-
1 infection 
 
Although the pathogenesis is poorly understood, HIV infection is associated with immune dysfunction 
which can further lead to complications in various organs of the body (Palmisano and Vella, 2011). 
This dysfunction usually results from disturbances in components of the immune system. Therefore, 
understanding how the immune system works in conjunction with its components is vital (Berger et al., 
2007). The immune system is divided into innate and adaptive immunity. Innate immunity is the 
response to acute infection which describes the first phase of HIV infection (Bruland, 2003). It consists 
of: (i) Interferons (IFNs) which have a wide variety of immunomodulatory and antiviral effects. (ii) 
Anti-Microbial Peptides (AMPs) which includes human alpha-and beta defensins that have been shown 
to have anti-viral activity including HIV-1 (Nguyen et al., 2014). 
 
(iii) Natural Killer (NK) cells that are essential in anti-viral or anti-tumor responses hence, when 
activated, they function by either killing the infected virus or tumor cells. (iv) Genital Epithelial Cell 
(GEC) responses whereby cells in the epithelium recognize and tailor a response to a wide variety of 
viral pathogens in the lumen of the FRT. (v) Dendritic Cells (DCs) and Macrophages which process 
viral information from the external environment to adaptive immunity of the host system (Nguyen et 
al., 2014). Adaptive immunity is the response to secondary infection (e.g. AIDS, which describes the 
chronic stage of HIV infection). It involves two types of responses: (a) humoral response, mediated by 
B-cells and (b) cellular response, mediated by T-cells. Both humoral and cellular responses are activated 
during virus infection (Bruland, 2003). 
 
Cellular T cells activate B cells to divide forming plasma cells that can produce antibodies to fight 
against antigens. They also produce memory B cells to protect the immune system against re-exposure 
to viral pathogens in future (Bruland, 2003). Antibodies produced prevent infection by targeting viruses 
for destruction by phagocyte cells, a process known as opsonisation, and by antibody dependent cell 
mediated cytotoxicity (ADCC). This is the process whereby lymphocyte cells lyse the target cell marked 
by an antibody (Bruland, 2003). Lymphocytes include Natural killer (NK) cells, Cytotoxic T cell 
(CD8+), Helper T cell (CD4+) and Memory B cell (Berger et al., 2007; Bruland, 2003). Changes in the 
B and T cells may increase HIV-1 infection.  
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As for humoral response, weak IgG responses may increase HIV-1 susceptibility (Nguyen et al., 2014). 
It is worth noting that HIV is capable of infecting monocytes, macrophages, DCs and CD4+ T cells 
(Herrera-Carrillo and Berkhout, 2015). However, DCs and CD4+ T cells are the main target cells of 
HIV and they are most abundant in the transformation zone of squamous ectocervix to columnar 
endocervix epithelium (Herrera-Carrillo and Berkhout, 2015; Nguyen et al., 2014).  
 
4.5 Interaction of DMPA & HIV-1  
 
Depot medroxyprogesterone acetate (DMPA) is a synthetic progestin derived from 17α-
hydroxyprogesterone which makes it a progesterone-based contraceptive (Nguyen et al., 2014). It is the 
second most related to the original progesterone after retroprogesterone. However, this progestin has a 
half-life longer than that of progesterone (Schindler et al., 2003). This method of contraception is widely 
used in SSA as well as in some areas with high prevalence of HIV-1. Clinical studies provided evidence 
that DMPA increases the risk of HIV-1 acquisition in women which in turn leads to AIDS progression 
(Tomasicchio et al., 2013). Such evidence has been proven in workers who engage themselves in 
commercial sex and those involved in serodiscordant partnership (Ralph et al., 2015).  
 
About 41 million women worldwide use Depo-provera as a way of preventing pregnancy (Hills-
Nieminen et al., 2015; Ralph et al., 2015). Thus, a normal dose of 150 mg is injected every three months 
(Tomasicchio et al., 2013). Depo-Provera acts by binding to and regulating the activity of steroid 
receptors (Tomasicchio et al., 2013). In this review, we discuss the effect of its binding specifically to 
the GR and the PR. However, it has been reviewed previously that DMPA affinity to bind to PR is 
higher as compared to its affinity of binding to GR (Schindler et al., 2003). Investigating different 
mechanisms via the GR and PR in response to the effect of DMPA on HIV-1 pathogenesis is of greater 
importance. 
 
These effects could include alterations in the mucosal microflora and thinning of the cervical or vaginal 
epithelium (Tomasicchio et al., 2013). Nguyen et al (2014) reported that: in the mucosal immune system 
of the FRT, DMPA inhibits the activity of CD8+ T cells and blocks the expression of perforins in T 
cells, it reduces antibody production, interferon β (IFN- β) production and antibody dependent 
cytotoxicity (ADCC). 
 
4.6 Antiretroviral (ARV) treatment 
 
Antiretroviral (ARV) has been the drug of choice against HIV/AIDS and it has been effective in 
reducing the number of death rates caused by the disease (Sharp and Hahn, 2011).  
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This treatment controls viral replication and reduces viral load in HIV infected individuals (UNAIDS, 
2013). Medical history revealed that people staying in well-developed countries are at an advantage of 
getting full access to the treatment. However, it’s unfortunate for those located in geographical areas 
like Africa as they are the most affected and yet treatment is limited (Palmisano and Vella, 2011). Per 
literature, North Africa has the poorest access in providing ARV therapy as it only caters for 11% of its 
population while SSA has been reported to take the lead in bettering access of providing ARV therapy 
because it caters for up to 7.5 million people (UNAIDS, 2013). Taken together, treatment is not 
prevailing everywhere and reliability on it for future curative abilities is uncertain (Sharp and Hahn, 
2011). It is also incapable of destroying the virus completely hence therapy should be made to be 
lifelong and health care systems should also be of reasonable cost (Palmisano and Vella, 2011). 
 
Up to date, there is still no cure for HIV/AIDS hence this disease is still predicted to increase soon due 
to untreated or undiagnosed HIV infected individuals (Lundgren et al., 2015; Palmisano and Vella, 
2011; Sharp and Hahn, 2011). In fact, previous studies performed on model simulation revealed that 
any 20% increase of HIV, particularly by injectable contraceptives would lead to 27,000 additional 
infections per year which could in turn lead to an increase of unintended pregnancies and birth, unsafe 
abortion as well as maternal death (Polis et al., 2014). Per Lundgren et al (2015), the risk of AIDS has 
never been zero among patients using antiretroviral therapy or even among those who had viral 
suppression in the process of receiving antiretroviral therapy. 
 
This calls for further research on treatments to use along with antiretroviral therapy to reduce disease 
among HIV positive patients (Lundgren et al., 2015). However, there are some inhibitors that have been 
reported to lower the viral load by interacting with the HIV viral life cycle. These include enfuvirtide, 
zidofudine, ritonavir, raltegravir, saquinavir and many more (Hicks and Gulick, 2009; Palmisano and 
Vella, 2011). Thus, new HIV infections and illnesses are prevented and many lives are saved by using 
ARV drug. 
 
4.7 Interaction of DMPA and ARV treatment 
 
Almost half of HIV infected adults are women of reproductive age who choose to prevent falling 
pregnant by making use of contraceptives such as DMPA (Watts et al., 2008). This contraceptive is 
recommended safe to be used by HIV infected women under ARV treatment because it doesn’t have 
effects on the levels of HIV RNA and CD4+ cell count (Hills-Nieminen et al., 2015; Watts et al., 2008). 
However, during the period of seroconversion to HIV-1; the use of DMPA has been reported to increase 
levels of HIV RNA as compared to non-use of DMPA during seroconversion (Watts et al., 2008). In 
addition to this, using DMPA for longer periods results in weight gain; the condition which may be 
worsened by using ARV treatment in HIV infected women (Bonny et al., 2006).  
20 
 
4.8 Background of the Progesterone receptor (PR) & the Glucocorticoid receptor (GR) 
 
These receptors belong to a superfamily of type 1 nuclear receptor (NR) (Mckay et al., 1999). Per 
phylogenetic analysis, they are classified under a subfamily of oxosteroids receptors (Bledsoe et al., 
2002). They both consist of various conserved domains at the centre but in this review, we focus more 
on the ligand binding domain (LBD) as is illustrated in a graphical representation of DMPA bound to 
both the PR and the GR (Figure 4.2). The PR and GR LBDs share a homology sequence of 50-57% 
(Africander et al., 2011). These LBDs are involved not only in binding of hormones but also in 
dimerization, chaperone association and binding coactivators (Bledsoe et al., 2002). 
 
 
Figure 4.2.  Graphical representation of DMPA ligand docked into the GR (A) and the PR (B) LBDs. 
 
Over the years, it has been shown that binding of a ligand to nuclear receptors causes the LBD to fold 
leading to formation of a hydrophobic pocket (Bledsoe et al., 2002). The activation function-2 (AF-2) 
domain, located within the LBD has been proven to be crucial in ligand regulation for transcriptional 
activity of the receptor because unlike activation function-1 (AF-1), the transcriptional activity of AF-
2 acts in the presence of a ligand (Africander et al., 2011; Aranda and Pacual, 2001; Bledsoe et al., 
2002). This AF-2 domain is also known to be a site where cofactors can be docked within the LBD 
(Africander et al., 2011). Present in the AF-2 domain is the LxxLL motif which interacts with some 
cofactors in the LBD (Africander et al., 2011; Bledsoe et al., 2002).  
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Upon activation of the receptor by the ligand, AF-2 is stabilised in its active conformation preventing 
interaction between LBD and corepressors but associating with coactivator proteins such as steroid 
receptor coactivator-1 (SRC-1) and transcriptional intermediary factor 2 (TIF2) (Africander et al., 2011; 
Bledsoe et al., 2002). 
 
4.9 General mechanism of type 1 nuclear receptors (GR & PR) 
 
In the absence of a ligand, the GR is in the cytoplasm where it’s complexed with heat shock proteins 
(HSPs) (De Bosscher et al., 2008). This prevents the GR from being activated as HSPs act as molecular 
chaperones to prevent activation (Africander et al., 2011). In contrast to the GR, location of the PR 
when not bound to the ligand is predominantly in the nucleus but part of the PR that is in the cytoplasm 
is also complexed with HSPs (Africander et al., 2011). Upon binding of a ligand, these receptors are 
highly phosphorylated leading to dissociation of HSPs and formation of NR dimer (Aranda and Pacual, 
2001). The NR dimer translocate from the cytoplasm to the nucleus where it binds to hormone response 
elements (HREs), followed by remodelling of the chromatin, components of the transcription machinery 
and cofactors recruitment to bring about positive transcription regulation (Africander et al., 2011). This 
process is referred to as transactivation (Sedwick, 2014).  
 
However, when transcription is regulated negatively, the process is termed transrepression. This can 
either be through a direct mechanism where receptors bind straight to DNA or via indirect mechanism 
where receptors interact with transcription factors bound to DNA like nuclear factor kappa B (NFϰB) 
and CCAAT-enhancer-binding protein (C/EBP) (Africander et al., 2011). The GR has been reported to 
be the most studied under transrepression processes; it follows indirect mechanism since it uses its GR 
monomer to bind NFϰB, a process known as tethering (Africander et al., 2011; Sedwick, 2014). 
Although the mechanism of tethering is less studied, it has been reported to activate transcription 
regulation (Africander et al., 2011).  
 
It is worth noting that whether regulation of transcription leads to activation or repression process 
depends mostly on whether the ligand is an agonist or antagonist. Generally, binding of an agonist to 
the receptor leads to transactivation whereas binding of an antagonist to the receptor results in 
transrepression (Africander et al., 2011). 
 
4.10 General mechanism of NFϰB transactivation 
 
It has been reported that expression of genes involved in the immune response is positively regulated 
by NFϰB. Such genes (including cytokines, immunoreceptors, viral proteins and many more) serve as 
targets during the process of NFϰB transactivation (Mckay et al., 1999; Zhong et al., 1998).  
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In the absence of a stimulus in the cell, the NFϰB dimer is in the cytoplasm where it is complexed with 
the inhibitor of NFϰB (IϰB), particularly IϰBα which is the most studied in a family of IϰB (Mckay et 
al., 1999; Oeckinghaus and Ghosh, 2009). However, in the presence of a stimulus, the IϰBα is 
phosphorylated by a complex of IϰB kinase (IKK), ser/thr kinases (IKK-1 & IKK-2). This in turn leads 
to dissociation of IϰBα which later undergoes proteosomal degradation from its exposure to 
ubiquitination, leaving the NFϰB dimer to translocate to the nucleus where it up-regulates the 
expression of genes to cause transcriptional activity (Mckay et al., 1999; Zhong et al., 1998). The 
general signalling pathway of NFϰB is brought about by the Rel p65/p50 heterodimer, hence it has been 
reported to be the most studied and found in almost all types of cells among the Rel NFϰB dimers 
(Mckay et al., 1999; Oeckinghaus and Ghosh, 2009).  
 
The Rel family is a term given to several related proteins that act as subunits of NFϰB (Mckay et al., 
1999). Members of the Rel family can form a homo or heterodimeric complex when they associate with 
each other as most of them form part in the Rel homology domain (RHD) made up of 300 amino acids 
(Mckay et al., 1999; Oeckinghaus and Ghosh, 2009). This RHD consist of DNA binding, dimerization 
and nuclear localization functions of NFϰB. In the p65/p50 heterodimer, the p50 subunit has been 
shown to lack the ability to cause transactivation since it doesn’t have the transactivation domain (TAD) 
like the p65 subunit (Oeckinghaus and Ghosh, 2009; Zhong et al., 1998). However, it is said that at least 
one Rel of the NFϰB dimer is enough to cause transactivation.  
 
4.11 Mediated response of the GR & the PR upon DMPA binding associated with increased risk of 
HIV-1 in women  
 
The GR and NFϰB signalling pathways have been recognized as important in regulation of immunity 
and inflammation because the immune response contains cytokines and cytokine induced genes 
regulated and activated through these pathways (Barnes et al., 2005; Mckay et al., 1999). The figures 
below summarise three possible biological mechanisms which could occur in the FRT via the GR/PR 
and NFϰB in the presence of DMPA, leading to an increase of HIV-1 infection in women. These 
mechanisms are explained as follows:  
 
(i) In the ectocervical (Ect1/E6E7) epithelial cell line, interleukin 12 (IL-12) p40 has been reported to 
be the cytokine induced gene regulated by the GR in the female genital tract and mediated by NFϰB to 
bring about transactivation (Louw-du Toit et al., 2014; Mckay et al., 1999). However, this IL-12p40 
contains none of the functional GR responsive elements hence transactivation of this mechanism is 
through binding of the ligand-activated GR to NFϰB which tethers to C/EBPβ that can attach itself in 
the IL-12p40 binding site (Figure 4.3). As for the PR mediated response, although the mechanisms 
involved are poorly understood, there is a high possibility that they could be similar to those of the GR 
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which are well studied (Africander et al., 2011). Like Bledsoe et al (2002) reported, the GR is 
homologous to the PR hence the functioning of their signalling pathways is closely related. This 
involves binding of the ligand, recruitment of coactivators as well as dimerization. Therefore, we 
postulate that DMPA or other agonist ligands could have a tendency of binding to the PR following the 
same GR mechanism as is explained above. However, the mechanism of DMPA-PR could be stronger 
and more effective as compared to that of DMPA-GR because of the difference in their binding affinities 
to DMPA (Schindler et al., 2003). 
 
Figure 4.3. Upon binding of DMPA to the GR, the HSP in the cytoplasm dissociates from the GR 
allowing the DMPA-activated GR to translocate to the nucleus. In the nucleus, the DMPA-activated 
GR binds to NFϰB which tethers to C/EBPβ that can bind IL-12p40 promoter to cause transactivation. 
Figure adapted from Africander et al (2011) & Louw et al (2014). 
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(ii) The chromatin structure in the nucleosome is made up of core histones around which DNA is wound. 
Modification of these histones is useful in determining which genes are repressed or activated during 
the process of transcription (Barnes et al., 2005). The histone acetylation process, controlled by histone 
acetyltransferases (HATs) has been reported to cause a major modification. This is a process whereby 
DNA unwinds due to change in charge of the core histone (Barnes et al., 2005). This change is caused 
by the presence of lysine residues in the core histone which are likely to be acetylated.  Histone 
acetylation causes the chromatin structure to change from being in a resting closed conformation to 
being in an activated open form (Barnes et al., 2005). Coactivators such as p300 and the Creb Binding 
Protein (CBP) have been reported to contain intrinsic HAT activity (Barnes et al., 2005). 
 
Interestingly, HIV transcriptional activation by viral protein R (Vpr) which is an accessory protein of 
HIV-1 is also mediated by the P300 NFϰB co-activator (Felzien et al., 1998). Both Vpr and NFκB are 
localised and regulated in the nucleus where Vpr co-operates through indirect mechanism with p300 to 
further regulate transcription of NFκB (Felzien et al., 1998).  Vpr is made up of 96 amino acids with a 
molecular weight of 11.38kDa (Guenzel et al., 2014; Wu et al., 2016; Zahoor et al., 2014). As a 
pleiotropic protein, it interacts with cellular factors inside the host through multiple mechanisms to 
bring about viral infection (Zahoor et al., 2014). Aranda and Pascual (2001) revealed that the CBP/P300 
can either bind directly or indirectly to nuclear receptors. Direct binding occurs through the NH2-
terminal domain while indirect binding occurs through interaction with p160 coactivators. 
 
In the event of indirect binding, a complex of corepressors such as SMRT/NcoR: mSin3 can bind to the 
GR heterodimer in the absence of a ligand by allowing recruitment of histone deacetylases (HDACs), 
a process known as deacetylation (Aranda and Pascual, 2001). Histone deacetylation causes chromatin 
compaction which leads to repression (Figure 4.4A). In contrast to this, the p160 coactivators such as 
SRC-1 have been reported to contain HAT activity in addition to its ability to interact with nuclear 
receptors. Moreover, binding of an agonist to the receptor has been reported to trigger hyperacetylation 
which is AF-2 dependent (Aranda and Pascual, 2001). Therefore, upon binding of DMPA to the GR, 
the CBP/P300: SRC-1 coactivator complex binds to the GR heterodimer through HAT to cause 
transactivation (Aranda and Pascual, 2001; De Bosscher et al., 2008) (Figure 4.4B). 
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Figure 4.4. A, in the absence of a ligand, the nuclear receptor (GR or PR) is bound to a corepressor 
complex such as SMRT/NCoR: mSin3 via the deacetylation process, this in turn causes repression. B, 
upon binding of a ligand, the GR heterodimer recruit histone acetyltransferases to bind the CBP/P300: 
SRC-1 coactivator complex, process known as acetylation. This coactivator complex then binds to the 
AF-2 domain to cause transactivation. Figure adapted from Aranda and Pascual, (2001). 
 
(iii) As part of the NFϰB general signalling pathway, protein kinase A catalytic subunit (PKAc) has 
been shown to be present in the cytosolic NFϰB: IϰBα complex held in its inactive state by the IϰBα 
(Zhong et al., 1998). Phosphorylation of IϰBα by IKK leads to dissociation of IϰBα as well as activation 
and dissociation of PKAc. The IϰBα gets degraded via ubiquitin pathway while the activated PKAc 
phosphorylates the p65 subunit of the NFϰB heterodimer allowing it to translocate to the nucleus for 
transcriptional activity (Mckay et al., 1999; Zhong et al., 1998) (Figure 4.5A). Interestingly, just like 
NFϰB, Vpr is localised and regulated in the nucleus where it co-operates with p300 to further regulate 
transcription of NFϰB (Felzien et al., 1998; Guenzel et al., 2014). 
 
In association with NFϰB, p300 has been reported to regulate transcriptional activity through 
phosphorylation of p65 by PKAc (Zhong et al., 1998). On the other hand, it has been shown to interact 
with NFϰB p65 Rel protein by acting as a coactivator in the p65 mediated transactivation. Moreover, 
the CBP/P300 has been identified as the GR transcriptional coactivator which enables transactivation 
upon binding of a ligand (Mckay et al., 1999). In summary, p300 has been reported to contain the 
receptor interacting domain (RID). Within this RID is the LxxLL motif which is also present in the AF-
2 domain located at the C-terminus within the LBD in nuclear receptors. This LxxLL motif causes 
transactivation by p300 to be AF-2 dependent (Aranda and Pascual, 2001). Interestingly, Unlike AF-1, 
the AF-2 domain plays a role in ligand regulation for transcriptional activity because it acts in the 
presence of a ligand and it’s also a site where cofactors can be docked within the LBD (Africander et 
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al., 2011; Aranda and Pascual, 2001). Thus, the AF-2 domain associate with coactivator proteins upon 
activation of the receptor by the ligand (Africander et al., 2011; Bledsoe et al., 2002). Therefore, upon 
binding of an agonist ligand such as DMPA to nuclear receptors (GR/PR); the p300 binds to the LBD 
through the LxxLL motif to cause transactivation. Based on this explanation, one can postulate that 
since p300 interacts with NFϰB transcription factor by acting as a coactivator in NFϰB p65 mediated 
transactivation, it is probable that the phosphorylated NFϰBp65/p50: p300 complex in the nucleus could 
bind to nuclear receptors through the p300 to further regulate transcriptional activity (Figure 4.5B).   
 
Sedwick (2014) recently reported that, just like the GR dimer would interact with NFαB p65 to cause 
transactivation, the GR monomer is also capable of exerting the same quality. Taken together, all these 
three mechanisms increase mRNA and protein secretion levels of proinflammatory cytokines in the 
ectocervical (Ect1/E6E7) epithelial cell line, region which is flooded by HIV-1 target cells (DCs and 
CD4+ T) in the FRT (Louw-du Toit et al., 2014; Nguyen et al., 2014). 
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Figure 4.5. A, The NFϰB p65/p50 heterodimer is in complex with IϰBα and PKAc in the cytoplasm. 
But in the presence of IKK, IϰBα is phosphorylated and exposed to ubiquitin pathway where it gets 
degraded. On the other hand, IKK causes PKAc to be activated which in turn phosphorylates the NFϰB 
p65/p50. In the nucleus p300 interacts with NFϰB transcription factor via the phosphorylated p65 
subunit to cause transactivation. B, Binding of DMPA to the GR causes the HSP in the cytoplasm to 
dissociate allowing the DMPA-activated GR to translocate to the nucleus where it could interact with 
the phosphorylated NFϰB p65/p50 via the p300 to cause further transcriptional activity. Figures adapted 
from Mckay et al (1999) and Louw-du Toit et al (2014).  
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4.12 Summary and conclusion 
 
The effect of Depo-Provera when bound to both the GR and the PR is likely to be a major cause of an 
elevated risk of HIV-1 infection in the female reproductive tract. This is because nuclear receptors can 
interact with NFϰB transcription factor in the nucleus as well as p300 which contains the RID. Within 
this RID is the LxxLL motif which is also present in the AF-2 domain located at the C-terminus within 
the LBD in nuclear receptors. This LxxLL motif causes transactivation by p300 to be AF-2 dependent 
which is interesting information because the AF-2 domain plays a crucial role in ligand regulation for 
transcriptional activity as it acts in the presence of a ligand and it’s also a site where cofactors can be 
docked within the LBD.  
 
Thus, the AF-2 domain associate with coactivator proteins upon activation of the receptor by the ligand. 
In addition to this, HIV transcriptional activation by Vpr which is the accessory protein of HIV-1 is 
known to be mediated by the p300 NFϰB coactivator. Therefore, various mechanisms regulated and 
mediated by the NFϰB and p300 through the GR and the PR are likely to cause transactivation upon 
binding of an agonist ligand as explained above. This increases mRNA and protein secretion levels of 
proinflammatory cytokines in the Ect1/E6E7 epithelial cell line, in turn, increasing the risk of HIV-1 
infection. Further investigations can still be carried out regarding how much DMPA dose is responsible 
for causing an increase of HIV-1 infection in women.  
 
4.13 Brief summary of docking approach 
 
Crystal structures of the GR in complex with dexamethasone [PDB code: 1M2Z (Bledsoe et al., 2002)] 
& that of the PR in complex with progesterone [PDB code: 1A28 (Williams & Sigler, 1998)] were 
downloaded from the protein data bank (PDB) for subsequent simulation whereas on the other hand, 
the DMPA ligand was downloaded separately from the Zinc database (Irwin & Shoichet, 2005). 
Docking preparation was carried out in AutoDock Vina (Trott & Olson, 2010) whereby a grid box with 
the spacing and exhaustiveness of 1Å and 8, respectively was designed for each of the GR and PR 
systems based on residues involved in their LBDs. Then the centre & dimension values were recorded 
to carry out molecular docking. 
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Abstract 
 
Over the 30 years since it was first identified, the HIV/AIDS epidemic has continued to increase across 
different countries. To date, women have become victims of HIV-1 infection as they use injectable 
hormonal contraceptives frequently, particularly depot medroxyprogesterone acetate (DMPA). This 
triggered a search as to which DMPA target is likely to contribute to the progression of HIV-1 
pathogenesis. As per literature, DMPA targets both the Glucocorticoid receptor (GR) and the 
progesterone receptor (PR) in the female reproductive tract (FRT). However, fewer computational work 
has been performed regarding the interaction of DMPA and these targets as well as their association 
with HIV-1 infection in women.  
 
Therefore, in this study we perform Molecular Dynamic (MD) simulation on both the GR and the PR 
systems in relation to DMPA as a way of validating their docking poses and binding energy trends. We 
also investigate the nature of their overall interaction themes using post-dynamic analysis. Our findings 
revealed that, the effect of DMPA binding to both the GR and PR could elevate the risk of HIV-1 
infection in women. The reason being that when DMPA is bound to GR and PR, it interacts with a few 
residues in the ligand binding domain (LBD) which could affect the stability state of these receptors. 
Furthermore, the results showed that DMPA is more comfortable binding to the PR as compared to the 
GR. 
    
Key words: HIV-1, DMPA, Glucocorticoid receptor, Progesterone receptor, Molecular docking, 
Molecular dynamics 
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5.1 Introduction 
 
Since it was first noted in the 1980s, acquired immune deficiency syndrome (AIDS) constitute one of 
the most serious crises currently facing human development (Piot et al., 2001). The causative agent for 
this disease is Human Immunodeficiency Virus (HIV) which can further be divided into HIV-1 and 
HIV-2 (Sharp & Hahn, 2011). However, HIV-1 is the most prevalent in countries such as sub-Saharan 
Africa (SSA) where infected women account for about 59% (Takalani et al.,2017). The major common 
mode of transmission is by heterosexual sex and mother-to-child transmission (Palmisano & Vella, 
2011; Piot et al., 2001). Within an estimation of 1.1 million children living with HIV in SSA, more than 
90% were reported to have acquired the infection from their mother (Piot et al., 2001).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
 
The emergence of HIV is not properly understood. However, it represents a major challenge to global 
public health (Piot et al., 2001). Given that the glucocorticoid receptor (GR) and the progesterone 
receptor (PR) are the main targets for DMPA (Figure 5.1) in the female reproductive tract (FRT) 
(Schindler et al., 2003), it is essential to perform in silico study of such interactions in association with 
increased risk of HIV-1 infection in women. Hence, we perform molecular docking and molecular 
dynamic (MD) simulations on the GR and PR protein systems in relation to DMPA to investigate their 
overall interaction themes using post dynamic analysis. Conducting MD simulations is advantageous 
in presenting conformational changes of a single molecule that has been examined over time and 
providing new insights to protein dynamics (Mhlongo & Soliman, 2015). 
 
 
 
Figure 5.1. Two-dimensional structural representation of DMPA ligand (Irwin & Shoichet, 2005) 
 
 
These insights could be gained by applying multiple-trajectory MD simulations as this enables 
conformational space sampling by reducing the impact of entrapment in local minima (Mhlongo & 
Soliman, 2015). 
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Herein, 50 ns multiple-trajectory MD simulations were employed to gain insight into the effect of 
DMPA on GR and PR. This was followed by binding free energy calculations, root mean square 
deviation (RMSD), root mean square fluctuation (RMSF) and radius of gyration (Rg) analyses. By 
conducting this research, we aim to provide new insights that will be useful in the development of new 
drugs against HIV/AIDS. 
 
5.2 Computational methods 
 
5.2.1 Preparation of protein structures 
 
The 3D agonist crystal structures of the GR in complex with dexamethasone [PDB code: 1M2Z 
(Bledsoe et al., 2002)] & that of the PR in complex with progesterone [PDB code: 1A28 (Williams & 
Sigler, 1998)] were retrieved from the protein data bank (PDB) for subsequent simulation. The DMPA 
ligand was downloaded separately from the Zinc database (Irwin & Shoichet, 2005). 
 
5.2.2 DMPA-GR and DMPA-PR complex preparations  
 
Crystal structures obtained from the PDB contained multiple chains but we only made use of chain A 
which was bound to dexamethasone in the GR and to progesterone in the PR. Unwanted water 
molecules, ligands and other protein chains except chain A, were removed from both structures and 
chain A was kept to generate the binding pockets for DMPA-GR and DMPA-PR complexes. The 
DMPA ligand was prepared in Molegro Molecular Viewer (MMV) and in Chimera (Yang et al., 2012) 
software. Taken together, the binding pockets of DMPA-GR and DMPA-PR were designed based on 
dexamethasone-GR and progesterone-PR ligand binding domains (LBDs), respectively (Bledsoe et al., 
2002; Williams & Sigler, 1998) (shown in Figure 5.2 and Table 5.1).  
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Figure 5.2. Ligplot diagrams showing A: Dexamethasone-GR (1M2Z) and B: Progesterone-PR 
interactions (1A28). Figures adapted from Wallace et al (1996). 
 
5.2.3 Molecular Docking 
 
To the best of our knowledge, there are no available x-ray structures of the GR and PR complexed to 
DMPA. Neither the “bound forms of agonistic PR and GR LBD structures” complexed to similar 
compounds with well-defined active sites. However, there are well-studied crystal structures (1M2Z 
and 1A28, as explained above) in the PDB bound to their respective agonist ligands (dexamethasone 
and progesterone, respectively). Hence, we made use of these structures to design the binding pockets 
of DMPA-GR and DMPA-PR, respectively since DMPA is also an agonist ligand. The docking 
procedure was conducted in AutoDock Vina software (Trott & Olson, 2010). For each of the GR and 
PR systems, a grid box (with the spacing and exhaustiveness of 1Å and 8, respectively) was designed 
to encompass the binding site residues shown in Figure 5.2A & B, respectively. Then the acquired grid 
box coordinates (shown in Table 5.1) were used to dock DMPA into GR and PR active site. Complexes 
of highest stability were analysed and saved (Figure 5.3) using Chimera software (Yang et al., 2012).  
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Table 5.1. Amino acid residues (Wallace et al.,1996) used to design the grid box for DMPA-GR and 
DMPA-PR protein systems, and the grid box coordinates for the respective systems. 
 
Protein structures                   LBD pocket residues                              Grid box centre & dimensions  
 
GR (1M2Z)                  Asn 564, Gln 570, Arg 611, Phe 749,             Centre                   Dimension  
                                      Gly 567, Gln 642, Thr 739, Ile 747,                     X= -48.194            X= 24 
                                     Leu 563, Met 560, Met 601, Tyr 735,                   Y= 12.78               Y= 20 
                                     Met 604, Leu 732, Cys 736, Phe 623.                   Z= -43.095            Z= 26 
                                    
PR (1A28)                     Arg 766, Gln 725, Met 759,                             Centre                   Dimension  
                                       Leu 718, Leu 797, Met 801,                             X= 22.737            X= 18 
                                       Asn 719, Met 909, Cys 891                              Y= 9.318              Y= 26 
                                      Thr 894, Tyr 890.                                               Z= 60.861            Z= 24 
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Figure 5.3.  Graphical representation of DMPA ligand docked into the GR (A) and the PR (B) active 
site. Diagrams constructed using Chimera software (Yang et al., 2012). 
 
5.2.4 Molecular dynamic (MD) simulation 
 
Molecular dynamic simulations were performed using Amber 14-intergrated GPU version of PMEMD 
engine (Andreas et al., 2012; Case et al., 2015). The coordinate and topology files were created using 
LEaP and antechamber modules integrated in amber 14 (Case et al., 2015). Thus, Tleap programme 
(Case et al., 2015) and general amber force field (GAFF) (Wang et al., 2004) were employed. Hydrogen 
atoms and counter-ions were added to ensure the systems are neutralised. In addition to this, the FF14SB 
force field of Amber 14 suite (Lindorff-Larsen et al., 2010) was used to further define parameters in the 
protein systems. These systems were submerged in a TIP3P (Jorgensen et al., 1983) water box such that 
no protein atoms were within 10 Å of box dimensions during simulations.  
 
Long-range electrostatic interactions with a direct space and van der Waals cut from 12 Å were treated 
using the particle mesh Ewald (PME) method (Harvey & De Fabritiis, 2009). Afterwards, a restraint 
potential of 500 kcal/mol Å2 was applied to the solute to carry out partial minimization of 2000 steps 
(1000 steps using steepest descend method and another 1000 steps using conjugate gradients). This was 
followed by 1000 steps of full minimization with no restrain carried out by conjugate gradients 
algorithm. With a harmonic restrain potential of 5 kcal/mol Å2 and a Langevin thermostat of 1/ps 
collision frequency, the systems were gradually heated from 0 to 300 K prior to minimization using a 
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canonical (NVT) ensemble MD simulation. Then isothermal isobaric (NPT) ensemble was used to 
equilibrate the systems at 300 K for 500 ps without restraint using Berendsen temperature coupling 
(Berendsen et al., 1984) to maintain pressure of the systems at 1 bar. The bonds of all hydrogen atoms 
at a time of 2 fs were constrained using SHAKE algorithm (Ryckaert et al., 1977) while all MD runs 
were performed using the SPFP precision model (Grand et al., 2013). Multiple 50 ns production MD 
runs were performed with a pressure coupling constant of 2 ps and a target pressure of 1 bar in an NPT 
ensemble at a temperature of 300 K.  
 
5.2.5 Post dynamic analysis 
 
Integrated with Amber 14 are the PTRAJ and CPPTRAJ programs (Case et al., 2015); these were used 
to analyse MD trajectories namely: root mean square deviation, Root of mean square fluctuation and 
Radius of gyration. Origin data software (http://www.originlab.com/) was used to plot results for 
analysis.  
 
5.2.6 Thermodynamic calculations 
 
The binding free energies of the GR and PR systems were calculated using the MM/PBSA method (Sun 
et al., 2014). From a 50 ns production run, these binding free energies were calculated considering 1000 
snapshots. Binding free energy calculations tell us about the ligand-receptor interactions and equations 
to describe such interactions are given by: 
 
ΔGbind = Gcomplex – Greceptor – Gligand   (1) 
Δ Gbind = Egas + Gsol – TΔS        (2) 
Egas = Eint + Evdw + Eele     (3) 
Gsol = GPB + GSA     (4) 
GSA = γSASA      (5) 
 
Where Egas is equivalent to energy gas phase evaluated from the FF14SB force field directly; Eint is 
equivalent to bond, angle & dihedral internal energies; and Evdw and Eele are equivalent to van der Waals 
and electrostatic energies, respectively. The solvation free energy is denoted by Gsol which can further 
be divided into polar electrostatic solvation energy (GPB) and non- polar electrostatic solvation energy 
components (GSA). A water probe radius of 1.4 Å is used to determine GSA estimated from the solvent 
accessible surface area (SASA). The TΔS is equivalent to the conformational temperature and total 
solute entropy upon binding.  
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5.3 Results and discussion 
 
5.3.1 Validation of molecular docking  
 
Apart from DMPA, there is experimental evidence (Hudson et al.,2007; Schindler et al., 2003; Zhang 
et al.,2007) of other agonist ligands which have been reported to interact with both GR and PR. This 
includes dexamethasone and prednisolone in the GR system as well as progesterone and norethindrone 
in the PR system. Hence, we retrieved half maximal effective concentration (EC50) values (shown in 
table 5.2) from the Binding Database (Chen et al., 2001; Chen et al., 2002) for these ligands complexed 
to their respective receptors and correlated them with their docking scores to further validate their 
docking poses. Docking was calculated as explained in section 5.2.3. The docked complexes and 
docking scores are shown in figure 5.4 and table 5.2, respectively.  
 
It is worth noting that less information provided in table 5.2 is due to a limited number of agonist ligands 
that interact with the GR and PR. To the best of our knowledge, these are the most studied agonist 
ligands for GR and PR with available EC50 values and that have also been approved by the food and 
drug administration (FDA). The GR system revealed an excellent correlation coefficients (R2) of 
0.83219 which can be attributed to the fact it is well studied, unlike the PR system which revealed a 
poor correlation of 0.5021. The results for these correlations are presented graphically in Figure 5.5 and 
5.6, respectively.  
 
The binding poses of GR and PR to ligands presented herein are consistent with previous experimental 
work carried out by Zhang et al (2007) and Hudson et al (2007). Per Neubig et al (2003), the EC50 value 
measures the potency of the drug hence it depends on both the affinity of a drug for its receptor as well 
as the efficacy which explains the drug-receptor interaction due to maximum biological effect (Neubig 
et al., 2003). The smaller the EC50 value, the more potent is the drug. Therefore, it can be deduced from 
our docking results and the EC50 values that DMPA has a higher binding affinity for the PR as compared 
to its affinity for the GR hence it is more potent when complexed to the PR.  
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Figure 5.4.  A, the GR protein structure docked with dexamethasone (light purple), prednisolone (light 
blue) and DMPA (brown). B, the PR protein structure docked with norethindrone (light blue), 
progesterone (light purple) and DMPA (brown). Diagrams constructed using Chimera software (Yang 
et al., 2012). 
 
Table 5.2. Docking scores (DS) and EC50 values of the GR & PR systems with their respective 
ligands 
 
Ligand                                                   DS (Kcal/mol)                                 EC50(nM)                             
 
Glucocorticoid receptor (GR) 
Dexamethasone                                             -8.8                                                   0.2 nM 
Prednisolone                                                  -8.4                                                   2.1 nM                                                                                                   
DMPA                                                           -8.1                                                    10 nM 
 
Progesterone receptor (PR) 
DMPA                                                           -9.7                                                  0.1 nM 
Progesterone                                                 -11.2                                                 0.9 nM 
Norethindrone                                              -11.0                                                  2.2 nM 
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Figure 5.5. Correlation graph showing docking scores (Kcal/mol) versus EC50 (nM) values for the GR 
system. 
 
 
Figure 5.6. Correlation graph showing docking scores (Kcal/mol) versus EC50 (nM) values for the PR 
system. 
 
5.3.2 Ligplot diagrams of DMPA interactions with GR and PR protein 
 
Given that DMPA is an agonist and agonist molecules bind in the bottom half of the LBD (Bledsoe et 
al., 2002; Nicolaides et al., 2010); DMPA was found to interact with which corresponds to Met 227 & 
Ile 231 in the active site of the GR system (Figure 5.7A) corresponding to M752 & I756, respectively 
in the human glucocorticoid receptor (hGRa) LBD sequence alignment (Figure 5.8). In the PR system 
(Figure 5.7B), residues Cys 210, Phe 224 & Met 228 interact with the ligand at the active site, 
corresponding to C891, F905 & M909, respectively in the human progesterone receptor (hPRb) LBD 
sequence alignment (Figure 5.8).  
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Figure 5.7. Ligplot diagram showing, A: DMPA-GR and B: DMPA-PR interactions. 
 
 
Figure 5.8. Sequence alignment of LBDs from selected steroid and nuclear receptors. The secondary 
structure determined by crystallography is in green (α helix) and blue (β sheet) whereas residues are 
highlighted by function: magenta (hormone binding) & yellow (dimerization). Navy blue and red 
triangles show the position of the intermolecular disulphide bond and the C-terminus of the HERαLBD 
used for crystallization, respectively. The activation function 2 core and “signature sequence” are 
underlined in red and navy blue, respectively. Figure adapted from Tanenbaum et al (1998).  
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5.3.3 Post dynamic analysis of DMPA-GR and DMPA-PR complexes 
 
5.3.3.1 Root mean square deviation (RMSD) 
 
RMSD of the C-alpha backbone for DMPA with respect to GR and PR was monitored throughout the 
50ns simulations to ensure stability within the systems. Apo (protein only) and bound (protein & ligand) 
average RMSD for the GR system was 6.83Å and 6.77Å, respectively. At the beginning of the 
simulation, apo conformation revealed a fluctuation of ~2.5 Å whereas bound conformation was stable 
from 4-30 ns and later on revealed a fluctuation of ~3Å within 30-40 ns. (Figure 5.9). These results 
demonstrated that DMPA is structurally related to GR. However, a great fluctuation within 30-40 ns 
towards the end of the simulation shows that the GR system could have undergone some conformational 
changes which could have resulted in the loss of stability of this complex.  
 
This can be explained by the interaction of DMPA with residues Met 752 and Ile 756 in the GR system 
as revealed in section 5.3.2. Both these residues are located in helix 12 (H12) of the hGRa LBD 
sequence alignment which is crucial in the formation of ligand binding pocket and the activation 
function-2 (AF-2) surface that facilitates interaction with coactivators (Nicolaides et al., 2010). Thus, 
upon binding of an agonist the receptor undergoes large conformational changes leading to alterations 
of H11 and H12 positions and the formation of an interaction surface that allows coactivators to bind 
to the AF-2 through their LxxLL motifs (Nicolaides et al., 2010).  
 
In contrast to the GR system, apo and bound average RMSD for the PR system was 1.13 Å and 1.40 Å, 
respectively (Figure 5.10). It is clear that average RMSD value for the apo form is lower than that of 
the bound form which can be attributed to DMPA interacting with Asn 38 as shown in the ligplot 
diagram (Figure 5.7B), corresponding to Asn 719 in the hPRb sequence alignment. Recent studies 
carried out by Zheng et al (2016) revealed that this is one of the key residues that has been found to be 
crucial for the dynamics of helix 12, helix 11 and the loop between them (895-908) resulting in stable 
apo-conformations of PR-LBD (Zheng et al., 2016). RMSD for this PR system was reasonably stable 
around 1 Å which confirms stable trajectories.  
 
Unlike in the GR system where residues interacting with DMPA in H11/H12 positions revealed large 
conformational changes, residues C891 (located in H11), F905 and M909 (located in H12) interacting 
with DMPA in the PR system resulted in a higher binding affinity and a more stable complex. Therefore, 
the large difference observed between RMSD behaviour of DMPA-GR and DMPA-PR confirms that 
progestins (DMPA in this case) bind better to the progesterone receptor as compared to the 
glucocorticoid receptor (Schindler et al., 2003). In addition to this, the ligand binding pocket of PR has 
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been reported to be flexible enough to accommodate ligands with different sizes and chemical species 
(Zheng et al., 2016). 
 
 
 
 
Figure 5.9. RMSD for DMPA-GR showing stability of apo and ligand bound conformations. The 
average for apo and bound were 6.83Å and 6.77Å, respectively. 
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Figure 5.10. RMSD for DMPA-PR showing stability of apo and ligand bound conformations. The 
average for apo and bound were 1.13Å and 1.40Å, respectively. 
 
5.3.3.2 Root of mean square fluctuation (RMSF) 
 
RMSF of the C-alpha atoms was calculated to examine the dynamic movement of amino acid residues 
in the GR and PR systems. Figure 5.11 shows DMPA-GR average RMSF; smooth RMSF was observed 
within residues 20-80 which can be attributed to DMPA interacting with residues Asn 39 and Gln 45 
as shown in figure 5.7A, corresponding to N564 and Q570 in the hGRa sequence alignment. These 
residues have been shown to contain hydrogen bonds which are important for holding the backbone of 
the steroid tightly in position (He et al., 2014). Thus, N564 interacts with the C-11 hydroxyl group of 
the steroid C ring whereas Q570 interacts with the C-3 keto group of the steroid A ring (He et al., 2014). 
This was followed by small fluctuations within residues 80-100 which per Bledsoe et al (2002) and He 
et al (2014) can be attributed to the presence of Phe 81, Phe 88 and Phe 98 within this region, 
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corresponding to F606, F613 and F623, respectively in the hGRa sequence alignment. Phenylalanine 
residues have been associated with solubility problems in the glucocorticoid receptor which may cause 
local instability that makes the protein prone to aggregation or misfolding (Bledsoe et al., 2002; He et 
al.,2014). Lastly in the RMSF-GR plot, we observed high fluctuations of ~2-2.5 Å at residues Glu180 
and Met220, corresponding to E705 and M745 in the hGRa sequence alignment. Based on the 
explanation provided in section 5.3.3.1 concerning alterations that occur in the H12 position upon 
binding of an agonist, it is clear that residue M745 also contributed to the large conformational changes 
that resulted upon binding of DMPA as it is also located in the H12 position and it revealed a high 
fluctuation.  
 
As for E705, long side chains of glutamic acids located in helix 9 of the GR have also been associated 
with solubility problems that may hinder crystallization. However, this residue is far away from the 
ligand binding pocket hence it doesn’t affect ligand-mediated GR transactivation or transrepression 
functions (He et al., 2014). In contrast to the GR system, DMPA-PR average RMSF (Figure 5.12) 
revealed much flexibility at residues K26, K109, K180, K238 and K245 corresponding to K707, K790, 
K861, K919 and K926 in the hPRb LBD sequence alignment, respectively. From these results it can be 
deduced that Lysine residues seem to play a major role of high conformational flexibility in the DMPA-
PR system. This can be attributed to change in loop dynamics of 703-712, 785-808 and 925-927 which 
may be correlated with ligand binding in agonistic conformation of the PR LBD (Williams and Sigler, 
1998; Zheng et al., 2016).  
 
Per Williams and Sigler (1998), the C-terminal extension (residues 922-933) which is crucial for 
hormone binding is tightly fixed in position by an antiparallel β-sheet interaction between amino acids 
925-927. K919 on the other hand which is found in helix 12 has been reported to stabilize helix 12 in 
the apo-form of PR-LBD through its interaction with Glu 723 in helix 3 (Zheng et al., 2016) whereas 
K861 which is found in helix 11 gets altered upon binding of an agonist to form an interaction surface 
that allows coactivators to bind to the AF-2 through their LxxLL motifs (Nicolaides et al., 2010).  
 
Therefore, a large difference observed between average RMSF values of DMPA-GR and DMPA-PR 
shows that even though residues in the GR system didn’t seem to fluctuate much as compared to the 
PR system, those that fluctuated (F606, F613, F623, E705 and M745) caused large conformational 
changes leading to some loss of its stability. Whereas large fluctuations observed in the PR system 
which were due to lysine residues didn’t disturb much of the stability state of this system, confirming 
that DMPA is indeed more comfortable binding to the PR as compared to the GR. 
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Figure 5.11. RMSF for DMPA-GR and apo conformations. The average for apo and bound were 
13.63Å and 14.31Å, respectively.   
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Figure 5.12. RMSF for DMPA-PR and apo conformations. The average for apo and bound were 
4.19Å and 4.01Å, respectively.  
 
 
5.3.3.3 Radius of gyration  
 
The radius of gyration (Rg) provides insight into the stability state of the system. However, this is a 
parameter linked to tertiary structural volume of a protein. Herein, average Rg for DMPA-GR was 
stable from 7-31 ns followed by a great fluctuation of ~3 Å within 31-41 ns (Figure 5.13). On the other 
hand, average Rg for DMPA-PR revealed a more compact system from the beginning of the simulation 
until the end, which confirms very high stability (Figure 5.14). These results are consistent with both 
our RMSD and RMSF results explained in section 5.3.3.1 and 5.3.3.2, respectively. Thus, a great 
fluctuation observed within 31-41 ns in the GR system could be explained by the H12 alterations which 
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occurred upon binding of DMPA whereas high stability in the PR system could be explained by a high 
number of lysine residues interacting with DMPA. The overall Rg profile for both DMPA-GR and 
DMPA-PR (apo and bound) showed large variations during the simulation time which indicates that 
both proteins are much flexible. This is also in accordance with previous reports which revealed that 
during MD simulations, radical conformational changes occur upon ligand binding (Kumalo & 
Soliman, 2016).  
 
 
 
 
Figure 5.13. Rg of DMPA-GR and apo conformations. The average for apo and bound were 22.20Å 
and 22.25Å, respectively.  
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Figure 5.14. Rg for DMPA-PR and apo conformations. The average for apo and bound were 18.22Å 
and 18.27Å, respectively. 
 
5.3.4 Thermodynamic calculations 
 
Binding free energy calculations for complexed systems (DMPA-GR and DMPA-PR) were conducted 
using the MM/PBSA method as is presented in Table 5.3. Average binding free energy (ΔGbind) of 
DMPA-GR was found to be -42.7928 kcal mol-1 whereas that of DMPA-PR was -56.6511 kcal mol-1. 
Thus, the overall binding free energy of DMPA-PR was higher than that of DMPA-GR by ~ 14 kcal 
mol-1. On the other hand, ΔEele (electrostatic) energy contributions to total binding free energy was 
revealed to be -3.9171 kcal mol-1 in the GR and -9.1289 kcal mol-1 in the PR, while ΔEvdw (van der 
Waals) contributions were revealed to be -50.7022 kcal mol-1 and -59.1000 kcal mol-1 in the GR and 
PR, respectively. Moreover, ΔGgas (bond, angle and dihedral energies) contributions were -54.6193 kcal 
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mol-1 in the GR and -68.2290 kcal mol-1 in the PR while ΔGsol (polar and non-polar electrostatic 
solvation energies) contributions were 11.5766 kcal mol-1 and 11.5778 kcal mol-1 in the GR and PR, 
respectively. It is worth noting that contributions of all components to binding free energy were also 
higher in the DMPA-PR system than in the DMPA-GR system. Thus, contributions of all components 
to binding free energy were higher in the DMPA-PR system than in the DMPA-GR system with the 
overall binding free energy of DMPA-PR higher than that of DMPA-GR by ~ 14 kcal mol-1. This is in 
great accordance with what has been reported by Govender et al (2014) that DMPA is a high affinity 
PR agonist and a full to partial GR agonist. 
 
Table 5.3. Binding free energy calculations (MM/PBSA) of DMPA-GR and DMPA-PR complexes 
 
Complexes      ΔGbind                 ΔEele              ΔEvdw               ΔGgas              ΔGsol                     
 
GR bound1   -43.4264±0.2164   -4.6704±0.2418   -51.3190±0.2254   -55.9893±0.3203   12.5626±0.2285 
      bound2    -42.3400±0.2320   -4.4488±0.2424   -50.3101±0.2288   -54.7589±0.3679   12.4189±0.2343 
      bound3    -44.3741±0.2337   -2.4663±0.1888   -52.4331±0.2338   -54.8994±0.2694   10.5253±0.1829 
      bound4    -41.0307±0.1960   -4.0829±0.2284   -48.7467±0.1923   -52.8296±0.3157   10.7989±0.2254 
  bound average    -42.7928              -3.9171              -50.7022               -54.6193              11.5766 
PR bound1   -56.5561±0.1645   -9.6677±0.1320   -58.8929±0.1491   -68.5606±0.2032   12.0045±0.1138 
      bound2   -56.9602±0.1686   -8.3772±0.1189   -59.4803±0.1584   -67.8575±0.1923   10.8973±0.0991 
      bound3   -56.9602±0.1686   -8.3772±0.1189   -59.4803±0.1584   -67.8575±0.1923   10.8973±0.0991  
      bound4   -56.1281±0.1784   -10.0937±0.1278   -58.5468±0.1679   -68.6405±0.1885 12.5124±0.0977 
   bound average   -56.6511              -9.1289               -59.1000               -68.2290             11.5778 
 
 
5.4 Understanding the mechanisms of action of GR and PR upon binding of DMPA in association 
with increased risk of HIV-1 infection in women 
 
The GR and PR are classified under steroid hormone receptors (SRs) which belong to the large nuclear 
receptor (NR) family (Fang et al., 2006). These NRs are transcription factors which get activated by 
hormones that bind through a ligand binding pocket located within the LBD. The LBD is made up of 
two transactivation domains, namely AF-1 and AF-2 (Nicolaides et al., 2010). The AF-1 domain is 
ligand-independent whereas the AF-2 domain acts in the presence of a ligand hence it plays a major 
role in ligand regulation for transcriptional activity. This AF-2 domain is located at the C-terminus 
within the LBD in nuclear receptors and it contains the LxxLL motif through which it interacts with 
some cofactors (Takalani et al., 2017).  
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Most often, unliganded receptors are located either in the cytoplasm or in the nucleus where they are 
complexed with heat shock proteins (HSPs). However, upon binding of a ligand these HSPs dissociate 
allowing receptors to form dimers competent to bind DNA at hormone response elements (HREs) (De 
Bosscher et al., 2008; Aranda and Pacual, 2001). During transcriptional control of gene expression by 
nuclear receptors, coactivators or corepressors are required to stimulate or repress, respectively, 
expression of the target gene (Sementchenko and Watson, 2000). However, it is worth noting that 
coactivators do not bind to DNA directly hence they associate with histone acetyltransferases (HATs).  
 
Per Barnes et al (2005), HATs control histone acetylation which is a process whereby DNA unwinds 
due to change in charge of the core histones around which DNA is wound in the chromatin structure of 
nucleosomes. This change is associated with the presence of lysine residues in histones which loosen 
their association with DNA (Barnes et al., 2005). Thus the chromatin structure opens up, allowing 
transcription factors that couldn’t bind DNA in a closed chromatin configuration and RNA polymerase 
II to bind, resulting in enhanced transcriptional activity. Conversely, corepressors together with histone 
deacetylases (HDACs) which control histone deacetylation reverse this acetylation process, resulting in 
gene silencing and decreased transcriptional activity (Barnes et al., 2005).  
 
Aranda and Pascual (2001) reviewed more interesting information on coactivators and histone 
acetylation; they revealed that Creb Binding Protein/p300 (CBP/P300) and p160 complexes function as 
enzymes hence, they have the ability to modify chromatin structure by acetylation (Aranda and Pascual, 
2001). The interaction of CBP/300 with nuclear receptors has been identified both in vivo and vitro and 
it was found that CBP/P300 binds directly and indirectly to nuclear receptors (Spencer et al., 1997). 
Direct binding is through interaction with the NH2-terminal whereas indirect binding is achieved by 
associating with p160 coactivators through the COOH-terminal region (Aranda and Pascual, 2001). In 
the case of p160 coactivators, steroid receptor coactivator-1 (SRC-1) possesses histone acetyltransferase 
activity that maps the COOH-terminal region (Spencer et al., 1997). Moreover, SRC-1 interacts with 
various nuclear receptors in an agonist and AF-2 dependent manner stimulating transcriptional activity 
in mammalian cells and yeasts (Aranda and Pascual, 2001).  
 
Given that HIV-1 provirus is packed into chromatin after integration in the host cell genome (Van Lint 
et al.,1996) and that HIV transcriptional activation by Viral Protein R (Vpr); an accessory protein of 
HIV-1 is mediated by the p300 transcription factor with HATs activity (Felzien et al., 1998;), one can 
postulate that conformational changes observed in RMSF plot of the DMPA-PR system (Figure 5.12) 
which were due to a high number of lysine residues resulted in histone acetylation and enhanced 
transcriptional activity. Thus, upon binding of an agonist DMPA to PR, the PR recruited 
CBP/P300:SRC-1 coactivator complex which associated with AF-2 at the C-terminal region. Because 
the CBP/P300:SRC-1 coactivator complex possesses HAT activity, this could have resulted in 
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chromatin decondensation and gene activation. It is worth noting that hyperacetylation is only triggered 
by agonists and is AF-2 dependent (Aranda and Pascual, 2001). The HAT activity is important for gene 
activation as mutation or removal of the HAT domain leads to loss of function for many transcription 
factors (Aranda and Pascual, 2001). Apart from SRC-1, P300/CBP-Associated Factor (p/CAF) which 
has also been reported to contain strong HAT activity, binds directly and indirectly to CBP/300 and 
nuclear receptors (Blanco et al., 1998; Korzus et al., 1998). Per Korzus et al (1998), the p/CAF HAT 
activity for nuclear receptor activation appears to be indispensable (Korzus et al., 1998).   
 
On the other hand, p300 has been reported to contain the LxxLL motif within its receptor interacting 
domain (RID) through which it interacts with the AF-2 domain in nuclear receptors to regulate 
transcriptional activity (Aranda and Pascual, 2001). Interestingly, this AF-2 domain is located within 
helix 12 (H12) in the LBD which gets altered upon binding of an agonist in order to create an interface 
for NR coactivators to bind (Hellal-Levy et al., 2000; Nicolaides et al., 2010). Therefore, we can also 
postulate that large conformational changes observed in the GR system at residues Met 752 and I756 
(Figure 5.9) and at residue M745 (Figure 5.11) found in H12 position of the hGRa sequence alignment 
resulted from helix 12 alteration as the GR associate with CBP/P300:SRC-1 coactivator complex upon 
binding of DMPA.  
 
Conversely, a higher binding affinity observed in the PR system at residues F905 and M909 in Figure 
10 and at residues K919 and K926 in Figure 5.12 found in H12 position of the hPRb sequence alignment 
can also be attributed to helix 12 alterations upon binding of DMPA as the PR associate with 
CBP/P300:SRC-1 coactivator complex. Taken together, mechanisms postulated herein could result in 
an enhanced ligand-dependent transcriptional activity which could in turn lead to increased risk of HIV-
1 infection in women. However, based on our results we noticed that upon binding of DMPA to both 
GR and PR, the PR system would lead to a more enhanced transcriptional activity as compared to the 
GR system that undergoes large conformational changes resulting in some loss of its stability.  
 
5.5 Conclusion 
 
This work revealed from a computational perspective that binding of DMPA to residues M745, M752 
& I756 within the GR LBD causes large conformational changes that could result in loss of stability of 
this complex whereas binding of DMPA to residues K707, K861, K790, F905, M909, K919 and K926 
within the PR LBD results in a higher binding affinity that could lead to a more enhanced transcriptional 
activity. However, knowing that the GR and PR LBDs share a homology sequence of 50-57%, both GR 
and PR remain important targets of DMPA. Thus, alterations in the GR and PR actions upon binding 
of DMPA may have major implications on the regulation of transcriptional activity, leading to an 
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increase of mRNA and virus production which further leads to increased risk of HIV-1 infection in 
women. 
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CHAPTER 6 
 
6. Conclusion and future recommendations 
 
Outlined in this chapter is the general conclusion of the entire thesis based on our findings and 
recommendations for future studies. 
 
6.1 General conclusion 
 
From a computational perspective, this work revealed that DMPA is structurally related to GR. 
However, binding of DMPA to residues M745, M752 & I756 within the GR LBD causes large 
conformational changes that could result in loss of stability of this complex whereas binding of DMPA 
to residues K707, K861, K790, F905, M909, K919 and K926 within the PR LBD results in a higher 
binding affinity that could lead to a more enhanced transcriptional activity. Thus, alterations in the GR 
and PR actions upon binding of DMPA may have major implications (especially in the PR) on the 
regulation of transcriptional activity, leading to an increase of mRNA and virus production which can 
further lead to increased risk of HIV-1 infection in women.  
 
Furthermore, and most importantly it revealed that the HAT activity possessed by the CBP/P300, p160 
SRC-1 and pCAF coactivators is crucial in facilitating nuclear-receptor mediated hormone signalling 
hence there is indeed a strong link between histone acetylation, chromatin remodelling and gene 
regulation, supporting the notion that was previously reported by Kevin Struhl in 1998.  Taken together, 
DMPA binds more tightly to the PR as compared to the GR; supporting the idea that although the PR 
mechanisms are poorly understood, there is a high possibility that upon binding of an agonist ligand 
such as DMPA they could follow mechanisms similar to those of the GR which are well studied to 
cause transactivation in the FRT (Louw et al., 2014; McKay and Cidlowski, 1999). This would increase 
mRNA and protein secretion levels of proinflammatory cytokines in the Ect1/E6E7 epithelial cell line, 
region which contains the main target cells (CD4+ T cells) of HIV (Louw et al., 2014; Nguyen et al., 
2014).  
 
On the other hand, previous literature revealed that p300 interact with NFϰB p65 Rel protein by acting 
as a coactivator in the p65 mediated transactivation and has been identified as the GR transcriptional 
coactivator which enables transactivation upon binding of a ligand (McKay and Cidlowski, 1999; 
Zhong et al., 1998). This p300 is found in the AF-2 domain at the C-terminus within the LBD and within 
the RID in nuclear receptors. Given that the LxxLL motif present in the AF-2 domain causes 
transactivation by p300 to be AF-2 dependent (Aranda and Pascual, 2001), it is probable that 
mechanisms regulated and mediated by NFϰB and p300 via the GR and PR are likely to cause 
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transactivation upon binding of an agonist ligand due to the presence of the LxxLL motif, leading to an 
elevated risk of HIV-1 infection in women. 
 
6.2 Recommendations and future studies 
 
This study does not discourage women from using DMPA as this would lead to lack of available and 
affordable birth control methods and increased rate of mother-to-child transmission in areas with high 
prevalence of HIV-1 (Hel et al., 2010). However, it encourages women living in areas with high 
prevalence of HIV-1 and using DMPA as their contraceptive method to seek diagnosis for reproductive 
tract infections (RTIs) as this gives rise to infections that may expose the non-infected to HIV-1 (Hel et 
al., 2010; Mmbaga, 2013). It also motivates these women to opt for counselling regarding polygamous 
relationships and making use of condoms during sexual intercourse (Morrison et al., 2012). Moreover, 
this study advises doctors, nurses or anyone who is responsible for injecting DMPA to patients to be 
careful with the sharing and reusing of needles during the process of administering DMPA as this has 
been associated with HIV-1 infection (Hel et al., 2010). Lastly and most importantly, it is worth noting 
that multiple factors such as dose, method used to select subjects of the study and size of the population 
would affect interpretation of studies differently. Therefore, great care should be taken when analysing 
the results (Hel et al., 2010). Herein, further investigations regarding how much DMPA dose is 
responsible for causing an increase of HIV-1 infection in women still needs to be conducted.  
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APPENDICES 
 
Appendix 1. Input files for docking DMPA into the GR system 
receptor = rec.pdpqt 
exhaustiveness = 8 
center_x = -48.194 
center_y = 12.78 
center_z = -43.095 
size_x = 24 
size_y = 20 
size_z = 26 
 
Appendix 2. Input files for docking DMPA into the PR system 
receptor = rec.pdpqt 
exhaustiveness = 8 
center_x = 22.737 
center_y = 9.318 
center_z = 60.861 
size_x = 18 
size_y = 26 
size_z = 24 
 
 
 
 
